Claims:

1. A solid implant comprising at least one parasiticidal compound having low aqueous solubility; and tabletting excipients including a bulking agent.

2. An implant as claimed in claim 1, which is adapted for subcutaneous implantation.

3. An implant as claimed in claim 1 or claim 2, wherein the parasiticidal compound has an aqueous solubility below 100 µg/ml.

4. An implant as claimed in claim 3, wherein the parasiticidal compound is an avermectin or a milbemycin.

5. An implant as claimed in claim 4, wherein the parasiticidal compound is doramectin.

6. An implant as claimed in any one of the preceding claims, wherein the bulking agent is lactose.

7. An implant as claimed in any one of the preceding claims, wherein the tabletting excipients include magnesium stearate.

8. An implant as claimed in any one of the preceding claims, wherein the tabletting excipients include a tablet disintegrant.

9. An implant as claimed in claim 8, wherein the tablet disintegrant is sodium starch glycolate.

10. An implant as claimed in any one of the preceding claims, which contains an antioxidant or a reducing agent.

11. An implant as claimed in claim 10, wherein the antioxidant is butylated hydroxy toluene or butylated hydroxy anisole.

12. An implant as claimed in any one of the preceding claims, which is suitable for sterilization, or has been sterilized, by irradiation.

13. An implant as claimed in any one of the preceding claims, wherein the tabletting excipients include polyvinyl pyrrolidone.

14. An implant as claimed in any one of the preceding claims, wherein the parasiticidal compound makes up between 10 and 60% of the implant, by weight.

15. An implant as claimed in any one of the preceding claims, which is adapted for implantation into the ears of cattle or sheep.

16. An implant as claimed in any one of the preceding claims, which is rod-shaped.

Replaced by Article 34

17. Use of an antioxidant or a reducing agent in a formulation containing an avermectin or a milbemycin for preventing degradation of the avermectin or milbemycin.

18. The use as claimed in claim 17, wherein the formulation is suitable for sterilization, or has been sterilized, by irradiation.

19. The use as claimed in claim 17 or claim 18, wherein the formulation is not liquid.

20. A process for the production of an implant as defined in claim 1, which comprises mixing the parasiticidal compound with the tabletting excipients and forming into the desired shape.

21. A method for the treatment or prevention of parasitic infections which comprises administering an implant as defined in any one of claims 1-16 to an animal in need of such treatment.